Thursday, June 2, 2016

Biogen updated analysis

I set out to write a quick article on Biogen, but one thing led to another, and it expanded into a relatively detailed analysis. I own Biogen, and while there are some negatives in the picture like declining interferon sales, on the whole it looks very positive for the next few years.

The full article:

Biogen (BIIB) Keys to Value in 2017 and Beyond

Keep diversified!

No comments:

Post a Comment